Gå direkt till innehåll
This project is a part of the EDCTP programme supported by the European Union.
This project is a part of the EDCTP programme supported by the European Union.

Pressmeddelande -

Scandinavian Biopharma has been awarded 7.4 million EUR from the EU for clinical trials of ETVAX® – a unique and newly developed vaccine against diarrheal disease

In international competition Scandinavian Biopharma has been awarded a grant of 7,4 million Euro for clinical trials of the ETEC vaccine ETVAX®. The clinical trials will be conducted in the African countries Zambia and The Gambia. The newly developed vaccine ETVAX® targets diarrhea caused by ETEC – an enteric bacteria responsible for hundred thousands of deaths annually among children in low- to middle income countries.

“We are very proud and pleased to be awarded this generous grant. To us, this is a recognition highlighting the importance of our research project that has the potential to save many children's lives in the future. The grant will accelerate the clinical development of our vaccine and be a valuable contribution for financing our planned Phase I study in Zambia and the following Phase IIb study in The Gambia. The Zambian trial is planned to start in the second quarter of 2019, and the Gambian study will follow thereafter”, says Björn Sjöstrand, CEO of Scandinavian Biopharma.

The project budget is largely funded by the EU Research and Innovation Framework Program, Horizon 2020 through the European and Developing Countries Clinical Trials Partnership Association (EDCTP) organization. The EDCTP funds clinical research to accelerate the development of new or improved drugs, vaccines and diagnostics against HIV/AIDS, tuberculosis, malaria as well as other poverty-related infectious diseases in sub-Saharan Africa, with a focus on clinical trials in phase II and III.


Scandinavian Biopharma

Scandinavian Biopharma is a Swedish research-based biotech company specialist in marketing and sales of vaccines, immunoglobulin’s, biodefense, antidotes and diagnostic tests.

Research and development is mainly focused on development of a new oral traveler’s diarrhea vaccine in collaboration with PATH Vaccine Solutions and University of Gothenburg.



Björn Sjöstrand

Björn Sjöstrand

Presskontakt VD +46 (0)72 712 51 20

Relaterat innehåll

Vi är ett forskningsbaserat biotechföretag fast beslutna att ge människor i hela världen ett längre och bättre liv.

Vi utvecklar det första vaccinet i världen mot diarré orsakad av ETEC för att skydda både barn och vuxna i endemiska länder och resenärer till högriskdestinationer.

Vi distribuerar ett brett sortiment av biologiska specialistläkemedel med fokus på vacciner och immunglobuliner.


Vår information på mynewsdesk riktar sig till journalister och media.

Scandinavian biopharma
Industrivägen 1, vån 4
171 48 Solna